Despite the attractive properties of CD74 as a therapeutic target and the significant activity of milatuzumab in preclinical MCL models, milatuzumab showed modest clinical activity, primarily due to rapid internalization of the antibody-antigen complex, resulting in a half-life of about 2 h. Here, CD74 is linked to mantle cell lymphoma.